Fig. 4: SLFN11 protein levels are not decreased following chemotherapy treatment; ATR or WEE1 inhibition restores DNA damage and replication stress in SLFN11-deficient cells.
From: SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
a Scheme for the protocol used to study SLFN11 protein evolvement following treatment with SN-38 in DU145 wild-type cells as further specified in “Methods”. Also shown are immunoblot analyses of SLFN11 and the indicated biomarkers. *, signal derives from a reprobing of GAPDH blots with pRPA S4/8. b Representative immunoblots of SLFN11 and the indicated biomarkers in DU145 isogenic pair treated for the indicated hours with gemcitabine monotherapy or gemcitabine/ATRi/WEE1i combinations. Similar results were obtained in a second, independent, experiment. *, aspecific bands.
